{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for amphotericin root_references_citation in Reference Text / Citation (approximate match)
Status:
Possibly Marketed Outside US
Source:
M017
(2020)
Source URL:
First approved in 2019
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT00638677: Phase 4 Interventional Completed Dental Caries
(2004)
Source URL:
First approved in 2018
Source:
Prodigen by Sterling Knight Pharmaceuticals LLC
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
SINGISO (0.8g) by Sae In Dang Co., Ltd.
(2016)
Source URL:
First approved in 2015
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 2012
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2009)
Source URL:
First approved in 2009
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2009)
Source URL:
First approved in 2009
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
INNER BEAUTY GEL by MISMIZBio Inc.
(2018)
Source URL:
First approved in 2004
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2001)
Source URL:
First approved in 2001
Source:
21 CFR 333E
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Herbs Natural Pain Killer by INNOVATECH CAPITAL CORPORATION
(2020)
Source URL:
First approved in 2001
Source:
21 CFR 333E
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04656730: Phase 4 Interventional Completed Irritable Bowel Syndrome
(2020)
Source URL:
First approved in 1999
Source:
M012
Source URL:
Class:
STRUCTURALLY DIVERSE